Moreover, an ongoing clinical trial aiming at evaluating the HER2-targeted TLR7/TLR8 mixed agonist ISAC BDC-1001 is enrolling individuals with HER2+ breast cancer (NCT04278144). This evidence concerns the gene TLR8 and breast carcinoma.